注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星氯化钠注射液治疗重症肺炎的效果观察

摘要
图/表
参考文献(16)
相关文章 (3)

全文: PDF (0 KB) HTML (26 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星氯化钠注射液治疗重症肺炎的疗效情况。方法选择2013年3月～2016年3月在我院收治的68例患者，依据治疗措施不同分为对照组（单独注射用头孢哌酮钠舒巴坦钠治疗）30例和联合治疗组（注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星氯化钠注射液治疗）38例。观察两组患者治疗前后血浆指标以及白细胞计数水平情况，观察两组患者临床疗效、不良反应发生情况。结果两组患者治疗前 PCT、WBC、CRP，差异无统计学意义（P＞0.05），治疗后对照组和联合治疗组患者 PCT、WBC、CRP均低于治疗前，差异有统计学意义（P＜0.05）；联合治疗组患者治疗后PCT、WBC、CRP均低于对照组，差异有统计学意义（P＜0.05）；联合治疗组患者临床总有效率高于对照组，差异有统计学意义（P＜0.05）。两组患者恶心、腹泻、头晕不良反应发生率差异无统计学意义（P＞0.05）。结论注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星氯化钠注射液治疗患者的临床效果明显，可明显降低PCT、WBC、CRP水平，不良反应少，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张小军
	叶建婷
	陈花

关键词 ：注射用头孢哌酮钠舒巴坦钠, 盐酸莫西沙星氯化钠注射液, 重症肺炎

Abstract：ObjectiveTo approach curative effect of treatment severe pneumonia by Sulperazon union Avelox.Methods68 patients with severe pneumonia admitted to our hospital from March 2013 to March 2016 were selected,According to the different treatment measures were divided into the control group(Sulperazon alone)30 cases and the combined treatment group (Sulperazon combined with Avelox treatment)38 cases.The plasma index and white blood cell count of two groups of patients with severe pneumonia before and after treatment were observed,and the clinical efficacy and adverse reactions of two groups of patients with severe pneumonia were observed.ResultsThere was no significant difference in pct,WBC and CRP between the two groups before treatment(P＞0.05).After treatment,the levels of pct,WBC and CRP in the control group and the combined treatment group were lower than those before treatment(P＜0.05).Pct,WBC and CRP in the combined treatment group were significantly lower than those in the control group(P＜0.05).The clinical total effective rate of severe pneumonia patients in the combined treatment group was higher than that in the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of nausea,diarrhea and dizziness between the two groups(P＞0.05).ConclusionThe treatment severe pneumonia by Sulperazon union Avelox,clinical effects is obviously,PCT and WBC、CRP are obviously decreasing,untoward effect is little,it is worth to be used.

Key words： Sulperazon Avelox Severe pneumonia

引用本文:

张小军;叶建婷;陈花. 注射用头孢哌酮钠舒巴坦钠联合盐酸莫西沙星氯化钠注射液治疗重症肺炎的效果观察[J]. 中国当代医药, 2018, 25(4): 156-158.
ZHANG Xiao-jun;YE Jian-ting;CHEN Hua. The curative effect detection of treatment severe pneumonia by Sulperazon union Avelox. 中国当代医药, 2018, 25(4): 156-158.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I4/156

[1]	王松芝.临床常见感染菌对注射用头孢哌酮钠舒巴坦钠的耐药性分析[J].临床和实验医学杂志，2013，12（6）：469-470.
[2]	Mogami R，Goldenberg T，de Marca PG，et al.Pulmonary infection caused by Mycobacterium kansasii：findings on computed tomography of the chest[J].Radiol Bras，2016，49（4）：209-213.
[3]	宋丽芹，李鑫，郑录.注射用头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗哮喘并发肺部感染的疗效分析[J].现代生物医学进展，2017，17（9）：1729-1731.
[4]	He GL，Chang YJ，Xu LP，et al.Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation[J].J Thorac Dis，2016，8（8）：2219-2225.
[5]	蔡凯旋.注射用头孢哌酮钠舒巴坦钠治疗小儿肺炎的临床效果分析[J].深圳中西医结合杂志，2015，25（3）：82-83.
[6]	Ramsay KA，Sandhu H，Geake JB，et al.The changing prevalenceofpulmonaryinfectioninadultswithcysticfibrosis：Alongitudinal analysis[J].Journal of CysticFibrosis16（2017）70-77.
[7]	马花平.头孢哌酮钠/舒巴坦钠（注射用头孢哌酮钠舒巴坦钠）治疗老年人肺部感染的临床分析[J].中国当代医药，2016，23（24）：115-117.
[8]	Haste L，Hulland K，Bolton S，et al.Development and characterization of a long-term murine model of Streptococcus pneumoniae infection of the lower airways[J].Infect Immun，2014，82（8）：3289-3298.
[9]	李志芳，段成城，董丽妍，等.老年心力衰竭肺部感染患者舒巴坦应用的效果分析[J].中华医院感染学杂志，2016，26（8）：1767-1769.
[11]	龙鼎，喻莉，杨军辉，等.替加环素联合头孢哌酮舒巴坦钠治疗广泛耐药鲍曼不动杆菌老年肺部感染疗效观察[J].中华实用诊断与治疗杂志，2016，30（5）：512-514.
[13]	李秀红，李波.注射用头孢哌酮钠舒巴坦钠对下呼吸道感染的抗菌效果及耐药趋势[J].中国药业，2013，22（8）：46-47.
[16]	郭利明，曾小飞，金家贵，等.盐酸莫西沙星氯化钠注射液治疗细菌感染性疾病的双盲随机对照研究[J].西部医学，2010，22（6）：1014-1016.
[10]	Virchow JC，Rodriguez-Roisin R，Papi A，et al.A randomized，double blinded，double-dummy efficacy and safety study of budesonide-for-moterol spiromax compared to budesonide-formoterol turbuhaler in adults and adolescents with persistent asthma[J].BMC Pulm Med，2016，17（16）：42.
[12]	Wen Xi-mao，Ren Nan，Wu An-hua，et al.Distribution of pathogens causing nosocomial infection monitored by national noso-comial infection surveillance system and changing trend[J].CJN，2011，21（2）：350-355.
[14]	Kuang Hai-yan，Hu Chun-xia，ZHOU Xiao-fei，et al.Clinical efficacy of cefoperazone/sulbactam in the treatment of infection in obstetrics and gynecology[J].PMB，2013，13（30）：5916-5918.
[15]	Mu Yan-ping，Wang Li-qing，Deng Xun，et al.Clinical efficacy and cost-effectiveness analysis for moxifloxacin with cefoperazone sodium/tazobactam sodium in the treatment of genitourinary infection[J].J practical medicine，2012，28（2）：287-289.